Tag Archives: Mayank Mamtani
B.Riley FBR Remains a Buy on Medicines Co (MDCO)
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Medicines Co (MDCO – Research Report) today and set a price target of $38. The company’s shares opened today at $27.22. Mamtani commented: “We see positive lateral read-through to MDCO
B.Riley FBR Remains a Buy on Viking Therapeutics (VKTX)
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $16. The company’s shares closed yesterday at $8.25. Mamtani noted: “On 3/13, after market
Spring Bank Pharmaceuticals Inc (SBPH) Receives a Buy from B.Riley FBR
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (SBPH – Research Report) today and set a price target of $24. The company’s shares closed yesterday at $10.47. Mamtani commented: “Pharmaceuticals (SBPH) reported 4Q18 financial
B.Riley FBR Thinks Arbutus Biopharma Corporation’s Stock is Going to Recover
B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma Corporation (ABUS – Research Report) today and set a price target of $9. The company’s shares opened today at $3.74, close to its 52-week low of $3.20. Mamtani
B.Riley FBR Thinks Galmed Pharmaceuticals’ Stock is Going to Recover
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Galmed Pharmaceuticals (GLMD – Research Report) today. The company’s shares closed on Friday at $7.56, close to its 52-week low of $4.84. Mamtani wrote: “4Q18 earnings release and conference call
B.Riley FBR Initiates a Buy Rating on Galectin Therapeutics (GALT)
Galectin Therapeutics (GALT – Research Report) received a Buy rating and a $11 price target from B.Riley FBR analyst Mayank Mamtani today. The company’s shares closed yesterday at $4.96. Mamtani commented: “Therapeutic Inc. (GALT) disclosed, in a press release, FY18
